Mei Sing Ong

Dr. Mei Sing Ong

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Child and Adolescent Mental Health
Verified
Journal Article
Closed access
PDF file
MOMei Sing Ong
Mei Sing Ong
MLMatthew Lakoma
Matthew Lakoma
SBSarah Gees Bhosrekar
Sarah Gees Bhosrekar
JHJason Hickok
Jason Hickok
LMLaura McLean
Laura McLean
DRDennis Ross‐Degnan
Dennis Ross‐Degnan

1 August 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
MOMei Sing Ong
Mei Sing Ong
SASteve Abman
Steve Abman
EAEric D. Austin
Eric D. Austin
JFJeffrey A. Feinstein
Jeffrey A. Feinstein
RHRachel K. Hopper
Rachel K. Hopper
KMKenneth D. Mandl
Kenneth D. Mandl

8 June 2021 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MOMei Sing Ong
Mei Sing Ong
SRSarah Ringold
Sarah Ringold
YKYukiko Kimura
Yukiko Kimura
LSLaura E. Schanberg
Laura E. Schanberg
GTGeorge A. Tomlinson
George A. Tomlinson
TIthe CARRA Registry Investigators
the CARRA Registry Investigators
Objective: To investigate the effects of early introduction of biologic disease‐modifying antirheumatic drugs (bDMARDs) on the disease course in untreated polyarticular juvenile idiopathic arthritis (JIA).Methods: We analyzed data on patients with polyarticular JIA participating in the Start Time Optimization of Biologics in Polyarticular JIA (STOP‐JIA) study (n = 400) and a comparator cohort (n = 248) from the Childhood Arthritis and Rheumatology Research Alliance Registry. Latent class trajectory modeling (LCTM) was applied to identify subgroups of patients with distinct disease courses based on disease activity (clinical Juvenile Arthritis Disease Activity Score in 10 joints) over 12 months from baseline.Results: In the STOP‐JIA study, 198 subjects (49.5%) received bDMARDs within 3 months of baseline assessment. LCTM analyses generated 3 latent classes representing 3 distinct disease trajectories, characterized by slow, moderate, or rapid disease activity improvement over time. Subjects in the rapid improvement trajectory attained inactive disease within 6 months from baseline. Odds of being in the rapid improvement trajectory versus the slow improvement trajectory were 3.6 times as high (95% confidence interval 1.32–10.0; P = 0.013) for those treated with bDMARDs ≤3 months from baseline compared with subjects who started bDMARDs >3 months after baseline, after adjusting for demographic characteristics, clinical attributes, and baseline disease activity. Shorter disease duration at first rheumatology visit approached statistical significance as a predictor of favorable trajectory without bDMARD treatment.Conclusion: Starting bDMARDs within 3 months of baseline assessment is associated with more rapid achievement of inactive disease in subjects with untreated polyarticular JIA. These results demonstrate the utility of trajectory analysis of disease course as a method for determining treatment efficacy.

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MOMei Sing Ong
Mei Sing Ong
JKJeff Klann
Jeff Klann
KLKueiyu Joshua Lin
Kueiyu Joshua Lin
BMBradley A. Maron
Bradley A. Maron
SMShawn N. Murphy
Shawn N. Murphy
KMKenneth D. Mandl
Kenneth D. Mandl
Background: Real‐world healthcare data are an important resource for epidemiologic research. However, accurate identification of patient cohorts—a crucial first step underpinning the validity of research results—remains a challenge. We developed and evaluated claims‐based case ascertainment algorithms for pulmonary hypertension (PH), comparing conventional decision rules with state‐of‐the‐art machine‐learning approaches. Methods and Results: We analyzed an electronic health record‐Medicare linked database from two large academic tertiary care hospitals (years 2007–2013). Electronic health record charts were reviewed to form a gold standard cohort of patients with (n=386) and without PH (n=164). Using health encounter data captured in Medicare claims (including patients’ demographics, diagnoses, medications, and procedures), we developed and compared 2 approaches for identifying patients with PH: decision rules and machine‐learning algorithms using penalized lasso regression, random forest, and gradient boosting machine. The most optimal rule‐based algorithm—having ≥3 PH‐related healthcare encounters and having undergone right heart catheterization—attained an area under the receiver operating characteristic curve of 0.64 (sensitivity, 0.75; specificity, 0.48). All 3 machine‐learning algorithms outperformed the most optimal rule‐based algorithm ( P <0.001). A model derived from the random forest algorithm achieved an area under the receiver operating characteristic curve of 0.88 (sensitivity, 0.87; specificity, 0.70), and gradient boosting machine achieved comparable results (area under the receiver operating characteristic curve, 0.85; sensitivity, 0.87; specificity, 0.70). Penalized lasso regression achieved an area under the receiver operating characteristic curve of 0.73 (sensitivity, 0.70; specificity, 0.68). Conclusions: Research‐grade case identification algorithms for PH can be derived and rigorously validated using machine‐learning algorithms. Simple decision rules commonly applied in published literature performed poorly; more complex rule‐based algorithms may potentially address the limitation of this approach. PH research using claims data would be considerably strengthened through the use of validated algorithms for cohort ascertainment.

4 August 2017 in Circulation Research
Verified
Journal Article
Open access
PDF file
MOMei Sing Ong
Mei Sing Ong
MMMary P. Mullen
Mary P. Mullen
EAEric D. Austin
Eric D. Austin
PSPeter Szolovits
Peter Szolovits
MNMarc D. Natter
Marc D. Natter
SAStephen L. Archer
Stephen L. Archer
Rationale: Pediatric pulmonary hypertension (PH) is a heterogeneous condition with varying natural history and therapeutic response. Precise classification of PH subtypes is, therefore, crucial for individualizing care. However, gaps remain in our understanding of the spectrum of PH in children. Objective: We seek to study the manifestations of PH in children and to assess the feasibility of applying a network-based approach to discern disease subtypes from comorbidity data recorded in longitudinal data sets. Methods and Results: A retrospective cohort study comprising 6 943 263 children (<18 years of age) enrolled in a commercial health insurance plan in the United States, between January 2010 and May 2013. A total of 1583 (0.02%) children met the criteria for PH. We identified comorbidities significantly associated with PH compared with the general population of children without PH. A Bayesian comorbidity network was constructed to model the interdependencies of these comorbidities, and network-clustering analysis was applied to derive disease subtypes comprising subgraphs of highly connected comorbid conditions. A total of 186 comorbidities were found to be significantly associated with PH. Network analysis of comorbidity patterns captured most of the major PH subtypes with known pathological basis defined by the World Health Organization and Panama classifications. The analysis further identified many subtypes documented in only a few case studies, including rare subtypes associated with several well-described genetic syndromes. Conclusions: Application of network science to model comorbidity patterns recorded in longitudinal data sets can facilitate the discovery of disease subtypes. Our analysis relearned established subtypes, thus validating the approach, and identified rare subtypes that are difficult to discern through clinical observations, providing impetus for deeper investigation of the disease subtypes that will enrich current disease classifications.

5 October 2023 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MOMei Sing Ong
Mei Sing Ong
NRNicholas L. Rider
Nicholas L. Rider
SSSarah Stein
Sarah Stein
PMPaul J. Maglione
Paul J. Maglione
AGAlison Galbraith
Alison Galbraith
JFJocelyn R. Farmer
Jocelyn R. Farmer